Dark

GNCA
Genocea Biosciences Inc
stock NASDAQ

At Close

5/20/2022 3:57:30 PM EDT

0.2128USD-3.141%(-0.0069)583,579

0.1680Bid 0.2557Ask 0.0877Spread IEX

Pre-market

5/18/2022 9:07:11 AM EDT

0.2100USD-4.415%(-0.0097)0

After-hours

1969-12-31

0.00USD0.000%(0.00)0

Overview Option Chain HistoricalMore

open chart

Market Cap

12.509M

CEO

William Clark

Headquarters

Cambridge, Massachusetts, USA

Industry

Biotechnology

Next Earnings

2022-08-04 (74d)

Last Split

2019-05-221for8reverse

NVAX PFE MRK AGEN NLNK VICL XLV

Jan 5, 2022

05:47PM EST Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January. GlobeNewswire Inc

Jan 4, 2022

07:22AM EST Genocea Biosciences Enters R&D Collaboration And Option Agreement With Janssen Benzinga

07:19AM EST Genocea Biosciences Enters Into Inhibigen R&D Collaboration And Option Deal With Janssen RTTNews

07:00AM EST Enters into Inhibigen R&D collaboration and option agreement with Janssen GlobeNewswire Inc

Oct 28, 2021

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

More News

Stats

Avg. Vol. 10 Day

4,207,374

Avg. Vol. 30 Day

2,259,304

Employees

Market Cap

12,509,129

Shares Out.

58,783,503

Float

31,426,085

On/Off Exchange

52%/48%

6 Month Beta

1.45

1 Year Beta

1.42

2 Year Beta

1.44

3 Year Beta

1.10

52 Week Low

0.16

52 Week High

2.68

SMA50

0.51

SMA200

1.03

1 Week

-1.02%

1 Month

-49.09%

3 Month

-79.34%

6 Month

-85.01%

1 Year

-90.83%

2 Year

-92.43%

5 Year

-99.55%

Profile

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.

GNCA Stock Summary

Genocea Biosciences Inc (NASDAQ:GNCA) stock price today is $0.2128, and today's volume is 583,579. GNCA is down -3.141% today. The 30 day average volume is 2,259,304. GNCA market cap is 12.509M with 58,783,503 shares outstanding.